Formulation and In Vitro Release Kinetics of a Sustained-Release Matrix Tablet for a Poorly Soluble Antihypertensive Drug
DOI:
https://doi.org/10.5281/zenodo.22662691Keywords:
sustained-release matrix tablet, poorly soluble antihypertensive drug, hydroxypropyl methylcellulose, dissolution release kinetics, design of experiments formulation optimizationAbstract
Background: A substantial proportion of antihypertensive drugs, including several dihydropyridine calcium channel blockers,
carvedilol, and angiotensin receptor blockers, fall into Biopharmaceutics Classification System (BCS) Class II, combining high
intestinal permeability with poor aqueous solubility. Converting such drugs into once-daily sustained-release matrix tablets
requires reconciling solubility enhancement with controlled release, since a rate-controlling hydrophilic matrix can leave an
intrinsically poorly soluble drug incompletely or erratically released. Objective: This review synthesizes the formulation science
underlying sustained-release matrix tablets for poorly soluble antihypertensive drugs, covering solubility-enhancement strategies,
hydrophilic matrix polymer selection, in vitro dissolution testing and release-kinetics modeling, and design-of-experiments-based
optimization. Methods: A narrative review of the peer-reviewed pharmaceutical formulation and biopharmaceutics literature was
conducted, with each candidate source individually verified against its publisher, PubMed, or Crossref record before inclusion;
sources were organized thematically around the physicochemical basis of BCS Class II limitations, matrix release mechanisms,
dissolution kinetics modeling, and formulation optimization. Findings: Solid dispersion and cyclodextrin complexation techniques
substantially increase the apparent solubility of poorly soluble antihypertensive drugs prior to matrix incorporation; hydroxypropyl
methylcellulose-based hydrophilic matrices, governed by combined diffusion and erosion mechanisms, remain the most extensively
validated sustained-release platform; the Korsmeyer-Peppas model, applied alongside zero-order, first-order, and Higuchi models,
provides the principal diagnostic tool for characterizing release mechanism; and design-of-experiments and quality-by-design
methodologies are needed to jointly optimize solubility-enhancement and matrix-polymer variables, which interact rather than
acting independently. Conclusions: Robust once-daily sustained-release matrix tablets for poorly soluble antihypertensive drugs
depend on the deliberate, sequential integration of solubility enhancement, mechanism-informed matrix design, and systematic
formulation optimization, an approach with direct relevance to improving antihypertensive adherence and long-term blood
pressure control.
References
Amidon GL, Lennernas H, Shah VP, Crison JR (1995) A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research, 12(3):413-420, DOI:10.1023/A:1016212804288.
Siepmann J, Peppas NA (2001) Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Advanced Drug Delivery Reviews, 48(2-3):139-157, DOI:10.1016/S0169-409X(01)00112-0.
Mutschler E, Knauf H (1999) Current status of sustained release formulations in the treatment of hypertension: an overview. Clinical Pharmacokinetics, 37(Suppl 1):1-6, DOI:10.2165/00003088-199937001-00001.
Schittny A, Huwyler J, Puchkov M (2020) Mechanisms of increased bioavailability through amorphous solid dispersions: a review. Drug Delivery, 27(1):110-127, DOI:10.1080/10717544.2019.1704940.
Loftsson T, Brewster ME (1996) Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. Journal of Pharmaceutical Sciences, 85(10):1017-1025, DOI:10.1021/js950534b.
Claxton AJ, Cramer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. Clinical Therapeutics, 23(8):1296-1310, DOI:10.1016/S0149-2918(01)80109-0.
Iskedjian M, Einarson TR, MacKeigan LD, Shear N, Addis A, Mittmann N, Ilersich AL (2002) Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clinical Therapeutics, 24(2):302-316, DOI:10.1016/S0149-2918(02)85026-3.
Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M (2008) Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ, 336(7653):1114-1117, DOI:10.1136/bmj.39553.670231.25.
Savjani KT, Gajjar AK, Savjani JK (2012) Drug solubility: importance and enhancement techniques. ISRN Pharmaceutics, 2012:195727, DOI:10.5402/2012/195727.
Potluri RHK, Bandari S, Jukanti R, Veerareddy PR (2011) Solubility enhancement and physicochemical characterization of carvedilol solid dispersion with Gelucire 50/13. Archives of Pharmacal Research, 34(1):51-57, DOI:10.1007/s12272-011-0106-3.
Zaghian M, Homayouni A, Keshavarz Z, Dayani L, Fakhari Z, Osooli FS (2025) Preparation and evaluation of valsartan orodispersible tablets using PVP-K30 and HPMC E3 solid dispersions by the solvent evaporation method. Research in Pharmaceutical Sciences, 20(4):566-579, DOI:10.4103/rps.rps_105_23.
Park C, Lee JH, Jin G, Ngo HV, Park JB, Tran TTD, Tran PHL, Lee BJ (2022) Release kinetics of hydroxypropyl methylcellulose governing drug release and hydrodynamic changes of matrix tablet. Current Drug Delivery, 19(5):520-533, DOI:10.2174/1567201818666210820101549.
Senarat S, Phaechamud T, Pornsawad P, Chaiya P (2025) Effervescence-modulated drug release from HPMC matrix tablets: mechanistic insight and numerical estimation of water and ibuprofen diffusivity. Journal of Drug Delivery Science and Technology, 113:107285, DOI:10.1016/j.jddst.2025.107285.
Yan G, Li H, Zhang R, Ding D (2000) Preparation and evaluation of a sustained-release formulation of nifedipine HPMC tablets. Drug Development and Industrial Pharmacy, 26(6):681-686, DOI:10.1081/DDC-100101284.
Devi D, Ghosh A, Mandal UK (2022) Sustained release matrix tablet of 100 mg losartan potassium: formulation development and in vitro characterization. Brazilian Journal of Pharmaceutical Sciences, 58:e20079, DOI:10.1590/s2175-97902022e20079.
Patel P, Pandya VP, Patel BV (2012) Formulation, evaluation and optimization of sustained release matrix tablets of captopril. Journal of Pharmacy and Bioallied Sciences, 4(5):77-78, DOI:10.4103/0975-7406.94146.
Higuchi T (1963) Mechanism of sustained-action medication: theoretical analysis of rate of release of solid drugs dispersed in solid matrices. Journal of Pharmaceutical Sciences, 52(12):1145-1149, DOI:10.1002/jps.2600521210.
Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA (1983) Mechanisms of solute release from porous hydrophilic polymers. International Journal of Pharmaceutics, 15(1):25-35, DOI:10.1016/0378-5173(83)90064-9.
Ritger PL, Peppas NA (1987) A simple equation for description of solute release II: Fickian and anomalous release from swellable devices. Journal of Controlled Release, 5(1):37-42, DOI:10.1016/0168-3659(87)90035-6.
Costa P, Sousa Lobo JM (2001) Modeling and comparison of dissolution profiles. European Journal of Pharmaceutical Sciences, 13(2):123-133, DOI:10.1016/S0928-0987(01)00095-1.
